HOUSTON, March 11, 2021 /PRNewswire/ -- Marker
Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology
company specializing in the development of next-generation T
cell-based immunotherapies for the treatment of hematological
malignancies and solid tumor indications, today announced that it
has commenced an underwritten public offering of shares of its
common stock. In addition, Marker expects to grant the underwriters
a 30-day option to purchase additional shares of its common stock.
All of the shares to be sold in the offering are to be sold by
Marker. The offering is subject to market and other conditions, and
there can be no assurance as to whether or when the offering may be
completed, or the actual size or terms of the offering.
Piper Sandler & Co. is acting
as the sole active book-running manager for the offering.
The proposed offering is being made pursuant to a shelf
registration statement, including a base prospectus, filed by
Marker that was declared effective by the Securities and Exchange
Commission ("SEC") on June 25, 2019.
The offering will be made only by means of a written prospectus and
prospectus supplement that form a part of the registration
statement. An electronic copy of the preliminary prospectus
supplement and accompanying prospectus relating to the offering
will be available on the website of the SEC at www.sec.gov. Copies
of the preliminary prospectus supplement, when available, and the
accompanying prospectus relating to the offering may be obtained by
contacting Piper Sandler & Co.,
Attention: Prospectus Department, 800 Nicollet Mall, J12S03,
Minneapolis, Minnesota 55402, by
telephone at (800) 747-3924 or by email at prospectus@psc.com. The
final terms of the offering will be disclosed in a final prospectus
supplement to be filed with the SEC.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of
any such state or other jurisdiction.
Forward-Looking Statements
This release contains forward-looking statements for purposes of
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Statements in this news release concerning the
Company's expectations, plans, business outlook or future
performance, and any other statements concerning assumptions made
or expectations as to any future events, conditions, performance or
other matters, are "forward-looking statements." Forward-looking
statements include statements regarding the timing, size and
completion of the proposed public offering. Forward-looking
statements are by their nature subject to risks, uncertainties and
other factors that could cause actual results to differ materially
from those stated in such statements. Such risks, uncertainties and
factors include, but are not limited to the risks set forth in the
Company's most recent Annual Report on Form 10-K and other SEC
filings that are available through EDGAR at www.sec.gov. Such risks
and uncertainties may be amplified by the COVID-19 pandemic and its
impact on our business and the global economy. The Company assumes
no obligation to update our forward-looking statements whether as a
result of new information, future events or otherwise, after the
date of this press release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/marker-therapeutics-inc-announces-proposed-public-offering-of-common-stock-301246042.html
SOURCE Marker Therapeutics, Inc.